RECRUITING

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Talk to us

Conditions

AdenovirusPrimary Immune Deficiency Disordercytotoxic t-lymphocytes

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

Official Title

A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection With Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients

Quick Facts

Study Start:2018-11-01
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03266627

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:1 Month to 79 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Mitchell Cairo, MD
CONTACT
914-594-2150
mitchell_cairo@nymc.edu
Lauren Harrison, RN
CONTACT
617-285-7844
lauren_harrison@nymc.edu

Principal Investigator

Mitchell Cairo, MD
PRINCIPAL_INVESTIGATOR
New York Medical College

Study Locations (Sites)

Children's Hospital Los Angeles
Los Angeles, California, 90027
United States
University of California San Francisco
San Francisco, California, 94158
United States
Children's Hospital of Colorado
Aurora, Colorado, 80045
United States
University of Colorado Denver
Aurora, Colorado, 80045
United States
Indiana University
Indianapolis, Indiana, 46202
United States
Johns Hopkins
Baltimore, Maryland, 21287
United States
Washington University
Saint Louis, Missouri, 63130
United States
Nationwide Children's Hosptial
Columbus, Ohio, 43205
United States
Children's Hospital of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
Medical College of Wisconsin/Children's Hospital of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: New York Medical College

  • Mitchell Cairo, MD, PRINCIPAL_INVESTIGATOR, New York Medical College

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-11-01
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2018-11-01
Study Completion Date2026-12-31

Terms related to this study

Keywords Provided by Researchers

  • adenovirus
  • primary immune deficiency disorder
  • cytotoxic t-lymphocytes

Additional Relevant MeSH Terms

  • Adenovirus
  • Primary Immune Deficiency Disorder